Comparing the cytotoxicity of taurolidine, mitomycin C, and oxaliplatin on the proliferation of in vitro colon carcinoma cells following pressurized intra-peritoneal aerosol chemotherapy (PIPAC)

Justyna Schubert 1*, Veria Khosrawipour 2, Haris Chaudhry 3, Mohamed Arafkas 4, Wolfram Trudo Knoefel 5, Alessio Pigazzi 3 and Tanja Khosrawipour 3,5

Abstract

**Background:** Besides its known antibacterial effect commonly used in intraperitoneal lavage, taurolidine has been observed to possess antineoplastic properties. In order to analyse this antineoplastic potential in a palliative therapeutic setting, taurolidine (TN) was compared to mitomycin C (MMC) and oxaliplatin (OX), known antineoplastic agents which are routinely used in intraperitoneal applications, following pressurized intra-peritoneal aerosol chemotherapy (PIPAC).

**Methods:** An in vitro model was established using a colon adenocarcinoma cell line (HT-29 human cells). Different experimental dosages of TN and combinations of TN, MMC, and OX were applied via PIPAC. To measure cell proliferation, a colorimetric tetrazolium reduction assay was utilized 24 h after PIPAC.

**Results:** We demonstrated a cytotoxic effect of TN and OX (184 mg/150 mL, \( p < 0.01 \)) on tumor cell growth. An increasing dosage of TN (from 0.5 g/100 mL to 0.75 g/150 mL) correlated with higher cell toxicity when compared to untreated cells (\( p < 0.05 \) and \( p < 0.01 \), respectively). PIPAC with OX and both OX and TN (0.5 g/100 mL) showed the same cytotoxic effect (\( p < 0.01 \)). No significant impact was observed for MMC (14 mg/50 mL, \( p > 0.05 \)) or MMC with OX (\( p > 0.05 \)) applied via PIPAC.

**Conclusions:** The intraperitoneal application of TN is mostly limited to lavage procedures in cases of peritonitis. Our results indicate a substantial antineoplastic in vitro effect on colon carcinoma cells following PIPAC application. While this effect could be used in the palliative treatment of peritoneal metastases, further clinical studies are required to investigate the feasibility of TN application in such cases.

**Keywords:** Colon carcinoma, Pressurized intra-peritoneal aerosol chemotherapy (PIPAC), Peritoneal metastasis, Taurolidine, Mitomycin C, Oxaliplatin
Background
Intraperitoneal chemotherapy (IPC) has gained increasing acceptance in the past 20 years and has since been frequently used and extensively studied. Limitations concerning drug delivery to solid cancer formations have been a major issue as they contribute to failure in systemic and IPC strategies [1, 2]. It had been argued that, to a large extent, an increased intra-tumoral pressure inhibits the penetration of anti-cancer drugs into these more solid cancer formations [3]. To overcome these limitations, pressurized intra-peritoneal aerosol chemotherapy (PIPAC) has been presented as an alternative option for IPC instead of conventional lavage [4]. Due to good clinical results [5], the current clinical and experimental focus has shifted toward the application of new drugs as well as more complex substances [6–8]. Meanwhile, a drug dosage increase of already applied substances is also under evaluation [9]. While clinical studies are promising, data indicates that there is a relevant amount of patients who do not show any histological regression of their peritoneal metastases (PM). This limited response to PIPAC therapy results in a fast progression of the disease. These patients could benefit from an optimised treatment with tauroli- dine delivery. During PIPAC, the abdominal cavity is filled with microdroplets in a pressurized environment [15–18]. To investigate whether adequate cytotoxicity of TN is achieved and to evaluate a possible clinical use, we aimed to compare TN at different concentrations to OX and MMC application during PIPAC. Both OX and MMC have been used as a single- or multi-drug treatment of PM. In this study, we used a well-established in vitro colon carcinoma model for PIPAC [19].

Methods

Cell cultures
A human colorectal in vitro model was established using a HT-29 cell line. The cell line was obtained from the Institute of Immunology and Experimental Therapy (Wroclaw, Poland). HT-29 cells were grown in Dulbecco's modified Eagle's medium (DMEM - high glucose, Sigma-Aldrich, Poznan, Poland) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Poland), 2 mmol/L glutamine, 100 IU/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich) at 36°C in a humidified 5% CO₂ incubator. Cells (1.4 x 10^5 per well) were seeded in 24-well plates (TC Plate 24 Well, Standard, F, Sarstedt AG & Co. KG, Germany) and incubated for 48 h.

PIPAC model and procedures
The ex vivo PIPAC model has been presented in numerous studies [6, 7]. A temperature of 36°C was established and continued for the entire procedure by placing the PIPAC box into a heated water bath. Two 24-well plates were positioned at the bottom of the PIPAC box. They were placed lateral of the aerosol jet spray produced by the microinjection pump (MIP®, Reger Medizintechnik, Rottweil, Germany). To further avoid direct exposure of the wells to the aerosol jet, both 24-well plates were placed under a bilaterally open plastic tunnel. The PIPAC box was then hermetically closed. A CO₂ capnoperitoneum was created within the box and continued for the entire application. TN (Taurolin® Ringer 0.5%, Berlin-Chemie AG, Berlin, Germany), MMC (Sigma-Aldrich), or OX (Medoxa, medac GmbH, Wedel, Germany) was applied onto the exposed tumor cells in aerosolised form.

Drugs doses
In current literature, the dosage of OX used for PIPAC has been described as 92 mg/m² body surface. This is delivered via 150 mL of 5% glucose solution. The solution is aerosolized in a capnoperitoneum of 12 mmHg. This dosage has demonstrated a significant cytotoxic effect in PIPAC application [19]. The calculations of drug volume and concentration of MMC were based on the data available for OX. We used 14 mg of MMC in 50 mL of 0.9% saline solution with 10% addition of DMSO (Sigma-Aldrich), which provided a full drug solubility. TN was applied in 3 different doses: 0.25 g, 0.5 g, and 0.75 g dissolved in 50, 100, and 150 mL, respectively. To evaluate the effect of a single-drug versus multiple-drug treatment on tumor cell toxicity, the following options were tested: for a single-drug PIPAC, MMC/OX/TN-0.25 g/TN-0.5 g/TN-0.75 g, and for a multidrug PIPAC, OX + MMC/OX + TN-0.5 g.

Exposure time
After 48 h of incubating the HT-29 cells, the culture medium was removed and replaced with 150 μL of fresh medium. Thereafter, PIPAC was performed in 2 steps. First, TN or MMC was applied followed by OX. Cells were exposed for an additional time of 30 min after PIPAC. Drug-treated cells were incubated at 36°C with 5% CO₂ following the period of exposure, all medium, including drug solution, was aspirated from the cells and replaced with fresh medium. Cells were incubated for 24 h at 36°C and 5% CO₂. Then, the MTS proliferation assay was performed.
**MTS test**

A colorimetric CellTiter 96® AQ™One Solution assay (Promega, Poland) was used to measure cell proliferation 24 h after PIPAC. The test was performed according to the manufacturer’s instruction with modifications. Briefly, the medium was removed from each well and replaced by 0.3 mL of fresh DMEM. Next, after 1 h of incubation at 36°C at 5%CO₂, an MTS-based reagent was added to each well and absorbance at 490 nm was detected using a microplate reader (Tecan, Basel, Switzerland). The untreated cells were used as a control group. For all groups, the percentage of proliferation was correlated to the control group.

**Statistical analysis**

Experiments were performed three times. All wells were counted without exclusion. To compare the independent groups, the Kruskal-Wallis analysis of variance on ranks was performed. Probability (p) values were defined as *p < 0.05, **p < 0.01, and *p > 0.05, with a p value <0.05 to be statistically significant. Data is shown as the mean standard deviation.

**Results**

**Effect of single-drug PIPAC on colon tumor cells growth**

PIPAC procedures were performed without major difficulties. Moreover, it was technically possible to apply TN despite its detergent properties as a liquid and its foam-creating characteristics. Among tested drugs that were incubated with HT-29 cells, TN (0.5 g/100 mL), and OX showed the most potent inhibition of cell growth when compared to untreated cells (*p < 0.05 and **p < 0.01, respectively). No significant effect was observed for MMC (*p > 0.05) (Fig. 1). However, the inhibitory effect of TN was dose dependent. The lowest applied dosage of TN (0.25 g/50 mL) did not exert any significant impact compared with the untreated control group. However, an increase in dosage correlated with higher tumor cell death. The cytotoxicity grew from 0.5 g to 0.75 g TN compared to the untreated control group (*p < 0.05 and **p < 0.01, respectively). The results of the TN dose escalation are summarized in Fig. 2.

**Effect of multi-drug PIPAC on colon carcinoma cell growth**

The combination of OX and TN did not show any increase of cytotoxicity versus OX alone. Compared to the untreated control group, there was no significant difference between PIPAC conducted with only OX and treatment augmentation with TN (0.5 g/100 mL). In both cases, the proliferation of cells was inhibited by approximately 50% (*p < 0.01, Fig. 3). Similar results were observed in the multi-drug combination of OX and MMC. The combined application of MMC and OX did not show significantly higher cell toxicity (*p > 0.05) when compared to the untreated control group (Fig. 4).

Although the combined application of MMC and tauroli- dine resulted in significantly higher cell toxicity (*p < 0.05) when compared to the MMC alone (Fig. 5), the combination of both drugs had similar results as tauroli- dine alone.

---

**Fig. 1** Effect of single-drug PIPAC (mitomycin C 14 mg/50 mL, tauroli dine 0.5 g/100 mL, and oxaliplatin 184 mg/150 mL) on colon carcinoma cell toxicity
Discussion
The search for new drugs and drug combinations for intraperitoneal applications has been ongoing [20–22]. The introduction of PIPAC has increased the interest in new substances which could improve overall cytotoxicity. The intraperitoneal cavity allows for the application of some substances that cannot be applied intravenously due to their toxicity or limited efficacy [10]. Nevertheless, while many possibly new substances are available, there has been little clinical experience on
these drugs. In contrast, TN is a substance that is clinically used in intra-abdominal surgery due to its antibacterial effects. There are some basic studies on its antineoplastic properties after its first use as an antiseptic agent, especially by Jacobi et al. [23]. So far, the clinical use of TN in PM has been neglected due to the availability of other, more established chemotherapeutic substances, such as OX and MMC. Since TN’s overall potential as an antineoplastic agent has been scarcely studied comparing its effects to known agents is presents challenges. Our experimental data confirm the antineoplastic activity of TN previously described by other authors [10, 11, 14] and compares this effect with current agents applied via PIPAC. Our findings further confirm previous recommendations which favour OX over MMC in the treatment of colon carcinoma [24–26]. Although MMC shows cytotoxicity on colon carcinoma cells, this effect seems to be far less than expected especially in comparison to OX and taurolidine. This effect has also been documented in clinical studies [26].
Data also indicate that the combined use of OX and MMC might possibly interfere with their overall efficacy and reduce their respective cytotoxic effects due to possible interactions. OX is known to exhibit pharmacological instability [27] as well as significant interference with other drugs [28], which might explain some of the observed effects. However, these data must be interpreted with caution as an in vitro cell experiment displays some limitations with respect to in vivo pharmacokinetics and possible influence on the immune system. A significant improvement for IPC could be reached using TN monotherapy or in combination with OX as an auxiliary treatment. Based on these data, more clinical studies are required to evaluate TN application’s safety and efficacy as well as possible toxicity in the treatment of PM. However, at least theoretically a clinical benefit from using OX as an auxiliary drug can be assumed.

Conclusion
TN shows a significant cytotoxic effect when applied with PIPAC and should be evaluated in further clinical studies. The cytotoxic effect of the low doses applied here is similarly effective to that of standard doses of oxaliplatin currently used. This might especially be of high value in cases of chemoresistant PM after multiple cycles of PIPAC.

Acknowledgements
Not applicable

Authors' contributions
JS did the laboratory analysis, data acquisition, and study design. VK did the supervision of the study and drafting and critical revision for important intellectual content of the manuscript. HC did the study design, data interpretation, and critical revision of the manuscript. MA did the critical revision for important intellectual content of the manuscript. AP did drafting and critical revision for important intellectual content of the manuscript. TK did the study design, laboratory analysis, data acquisition, and manuscript drafting. All authors read and approved the final manuscript.

Funding
This study was funded by institutional funds.

Availability of data and materials
Our data is freely available if any scientist wishes to use them.

Ethics approval and consent to participate
No patient or animal tissue or data was needed for this in vitro cell study. The used human cancer cells lines were commercially acquired. Therefore, no approval of the ethics committee was required or applicable for the study.

Consent for publication
This is not applicable since our manuscript does not include any individual person’s data.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Food Hygiene and Consumer Health Protection, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland. 2Department of Orthopedic and Trauma Surgery, Ortho-Klinik Dortmund, Dortmund, Germany. 3Division of Colorectal Surgery, Department of Surgery, University of California Irvine (UCI), California, USA. 4Department of Plastic Surgery, Ortho-Klinik Dortmund, Dortmund, Germany. 5Department of Surgery (A), University-Hospital Düsseldorf, Düsseldorf, Germany.

Received: 13 March 2019 Accepted: 20 May 2019
Published online: 03 June 2019

References
1. Lu Z, Wang J, Wentjes MG, Au JL. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 2010;6(10):1625–41.
2. Au JL, Jang SH, Wentjes MG. Clinical aspects of drug delivery to tumors. J. Controlled Release. 2002;78(1-3):81–95.
3. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271:58–65.
4. Solà W, Hetzel A, Nadiradze G, Sagnallè E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26(7):1849–55.
5. Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized intra peritoneal aerosol chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS One. 2017;11(10):e139145.
6. Mikolaiczky A, Khosrawipour V, Schubert J, Grzesiak J, Chaudhry H, Pigazzi A, Khosrawipour T. Effect of liposomal doxorubicin in pressurized intra-peritoneal aerosol chemotherapy (PIPAC). J Cancer. 2018;9(23):4301–5.
7. Mikolaiczky A, Khosrawipour V, Schubert J, Chaudhry H, Pigazzi A, Khosrawipour T. Particle stability during pressurized intra-peritoneal aerosol chemotherapy (PIPAC). Anticancer Res. 2018;38(8):4645–9.
8. Nowacki M, Wisniewski M, Werengowska-Ciecwierz K, Roszek K, Czarnecka J, Jakubowska I, Kloskowski T, Tyloch D, Debinski R, Pietkun K, Pokrywczynska M, Grzanka D, Czajkowski R, Drewa G, Jundzill A, Agynj JK, Habib SL, Terzyk AP, Drewa T. Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis, Oncotarget. 2015;6(26):22776–98.
9. Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Förster E, Osma A, Agyin JK, Habib SL, Terzyk AP, Drewa T. Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy (PIPAC). Anticancer Res. 2016;36(9):4595–600.
10. Braumann C, Ordemann J, Wildbrett P, Jacobi CA. Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumor growth in rats. Clin Exp Metastasis. 2000;18(7):547–52.
11. Jacobi CA, Rotermund J, Wengler F, Volk HD, Müller JM. Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model. Langenbecks Arch Chir. 1997;382(4 Suppl 1):S31–6.
12. Frieling H, Lauer KS, Gründling M, Uschenko T, Weissner K, Kanellopoulou T, Lehmann C, Wendt M, Pavlovic D. Peritoneal instillation of taurolidine or polyhexanides modulates intestinal microcirculation in experimental endotoxemia. Int J Colorectal Dis. 2007;22(7):807–17.
13. Schneider A, Sack U, Rothe K, Bennik J. Peritoneal taurolidine lavage in children with localised peritonitis due to appendicitis. Pediatr Surg Int. 2005;21(6):445–8.
14. Akkus A, Gülmen M, Cevik A, Bildik N, Sad O, Oztürk E, Barjik NO. Effect of perioperative lavage with taurolidine on primary colonic anastomosis in a rat model of secondary peritonitis. Surg Today. 2006;36(5):436–40.
15. Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J, Stintz M, Giger-Pabst U. Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc. 2017;31(4):1778–84.
16. Khosrawipour T, Wu D, Bellendorf A, Mohanaraja KE, Diaz-Carballo D, Khosrawipour V. Feasibility of single tumor spot treatment in peritoneal carcinomatosis via close range doxorubicin impaction in pressurized intra-peritoneal aerosol chemotherapy (PIPAC). J Clin Exp Oncol. 2017;6(3). https://www.scitechnol.com/peer-review/feasibility-of-single-tumorspot-treatment-in-peritoneal-carcinomatosis-via-close-range-doxorubicin-impaction-in-pressurized-intrap-sG1B.php?article_id=6082.

17. Khosrawipour V, Mikolajczyk A, Schubert J, Khosrawipour T. Pressurized intra-peritoneal aerosol chemotherapy (PIPAC) via endoscopical microcatheter system. Anticancer Res. 2018;38(6):3447–52.

18. Khosrawipour T, Schubert J, Khosrawipour V, Chaudhry H, Grzesiak J, Arañas M, Mikolajczyk A. Particle stability and structure on the peritoneal surface in pressurized intra-peritoneal aerosol chemotherapy (PIPAC) analysed by electron microscopy: first evidence of a new physical concept for PIPAC [accepted for publication on Oncol Letters].

19. Khosrawipour V, Diaz-Carballo D, Acikelli AH, Khosrawipour T, Falkenstein TA, Wu D, Zieren J, Giger-Pabst U. Cytotoxic effect of different treatment parameters in pressurized intraperitoneal aerosol chemotherapy (PIPAC) on the in vitro proliferation of human colonic cancer cells. World J Surg Oncol. 2017;10(1):43.

20. Khosrawipour V, Bellendorf A, Khosrawipour C, Hedayat-Pour Y, Diaz-Carballo D, Förster E, Mücke R, Kabakci B, Adamietz IA, Fakhrian K. Irradiation does not increase the penetration depth of doxorubicin in normal tissue after pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in an Ex Vivo Model. In Vivo. 2016;30(S1):593–7.

21. Khosrawipour V, Giger-Pabst U, Khosrawipour T, Chaudhry H, Diaz-Carballo D, Förster E, Böse-Ribeiro H, Adamietz IA, Zieren J, Fakhrian K. Effect of irradiation on tissue penetration depth of doxorubicin after pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in a novel ex-vivo model. J Cancer. 2016;7(8):910–24.

22. Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U. Exploring the spatial drug distribution pattern of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2016;23(4):1220–4.

23. Jacobi CA, Ordemann J, Böhm B, Zieren HU, Sabat R, Müller JM. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. Am J Surg. 1997;174(3):359–63.

24. Levine EA, Votanopoulos K, Shen P, Russell G, Fenstermaker J, Mansfield P, Bartlett D, Stewart JH. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226(4):344–43.

25. van Eden WJ, NF M, Woensdregt K, ADR H, Boot H, AGJ A. Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44(2):220–7.

26. Leung V, Huo YR, Liao W, Morris DL. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(1):144–9.

27. Kwéékéél DM, Geldenblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005;30(2):90–105.

28. Basso M, Dadduzzi V, Rossi S, D’Argento E, Strippoli A, Di Salvatore M, Orlandi A, Zurlò V, Di Noia V, Barone C. The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the ‘unexplainable’. Per Med. 2018;15(4):319–27.